SOURCE: Healtheuniverse, Inc.

June 05, 2007 09:08 ET

Healtheuniverse Patented Non-Embryonic Stem Cell Technology in Development for Use in the $15 Billion Plastic, Reconstructive, and Cosmetic Surgery Market

COVINA, CA--(Marketwire - June 5, 2007) - Healtheuniverse Inc. (PINKSHEETS: HLUN), a biotechnology development firm engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells, announced today that the Company's adipose derived stem cell technology is under development for use in the $15 billion worldwide plastic surgery and cosmetic surgery market. The Company intends to sell its proprietary technology through packaged products and licensing agreements, once human clinical trials are completed, to plastic and cosmetic surgeons as a simple way for the industry to utilize our proprietary technology worldwide.

Cosmetic surgery can be performed with stem-cell generated natural tissues instead of synthetic implants. Saline and silicone implants for breast augmentation may rupture, leak, and interfere with breast cancer detection on mammograms. Stem cell generated natural tissue implants created through the use of the Company's commercially packaged product line could provide a superior product and also avoid these problems.

The market for plastic, reconstructive, and cosmetic surgery procedures today exceeds $15 billion per year. It's estimated that cosmetic surgery procedures represent approximately $10 billion of industry revenues. Plastic Surgery encompasses both reconstructive and aesthetic surgery, commonly referred to as cosmetic surgery. While not essential to physical health, aesthetic surgery can improve the appearance of normal body features and enhance self-image.


HEALTHeUNIVERSE Inc. is engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in disease related commercial applications. More information on Healtheuniverse is available online at

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse, Inc.
    Investor Relations
    Email Contact